Zacks Research Weighs in on Novartis’ Q1 Earnings (NYSE:NVS)

Novartis AG (NYSE:NVS) – Equities research analysts at Zacks Research cut their Q1 2026 EPS estimates for Novartis in a note issued to investors on Wednesday, January 15th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings per share of $2.07 for the quarter, down from their previous estimate of $2.09. The consensus estimate for Novartis’ current full-year earnings is $7.63 per share. Zacks Research also issued estimates for Novartis’ Q2 2026 earnings at $2.25 EPS and FY2026 earnings at $8.96 EPS.

Other equities analysts have also issued research reports about the stock. HSBC lowered shares of Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. Finally, BMO Capital Markets boosted their target price on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research note on Wednesday, October 30th. Two equities research analysts have rated the stock with a sell rating and seven have issued a hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $121.50.

Novartis Trading Up 2.2 %

NYSE:NVS opened at $99.69 on Monday. Novartis has a 12 month low of $92.35 and a 12 month high of $120.92. The firm has a market cap of $203.76 billion, a price-to-earnings ratio of 11.58, a P/E/G ratio of 1.34 and a beta of 0.57. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55. The company’s 50 day moving average is $100.44 and its 200-day moving average is $108.94.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The firm had revenue of $12.82 billion for the quarter, compared to analyst estimates of $12.62 billion. During the same quarter last year, the firm earned $1.74 earnings per share.

Institutional Trading of Novartis

Several institutional investors and hedge funds have recently added to or reduced their stakes in NVS. Canada Pension Plan Investment Board bought a new stake in Novartis during the 2nd quarter worth about $64,610,000. Bank of Montreal Can increased its stake in shares of Novartis by 343.5% in the 2nd quarter. Bank of Montreal Can now owns 657,903 shares of the company’s stock valued at $70,652,000 after acquiring an additional 509,567 shares during the last quarter. World Investment Advisors LLC bought a new stake in shares of Novartis in the 3rd quarter valued at about $30,063,000. Fisher Asset Management LLC increased its stake in shares of Novartis by 15.7% in the 3rd quarter. Fisher Asset Management LLC now owns 1,706,009 shares of the company’s stock valued at $196,225,000 after acquiring an additional 231,851 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new stake in shares of Novartis in the 2nd quarter valued at about $22,979,000. 13.12% of the stock is owned by institutional investors.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.